GENEVA (Reuters)—Governments are not doing all they should to tackle the deadly Middle East Respiratory Syndrome, a committee of health experts at the World Health Organization said on Thursday. The WHO’s emergency committee, which meets regularly to consider the international response to the disease, said in a statement that its advice had not been completely…
Resunab Fast Tracked to Treat Scleroderma, Plus, Infliximab Biosimilars in Europe
The FDA has fast-tracked the development of a drug to treat systemic sclerosis, or scleroderma; initial clinical trials started in June. Also, a major hospital group in France has selected the biosimilar infliximab to treat its patients with RA, Crohn’s disease and psoriasis…
Alcohol Use Complicates Chronic Disease Management in Teens
NEW YORK (Reuters Health)—High school students with chronic medical conditions who drink alcohol are more likely than their nondrinking peers to forget or skip taking their medications, according to an online survey. “I was surprised to see such a clear association between alcohol use and medication nonadherence—a finding which really brings home the need to…
Can We Get Closer to a Cure for RA?
Despite new therapeutics, progress for RA patients has virtually stalled over the past 10 years. In this article, the authors discuss many options to advance to a cure and the evidence for them, including the combination of low-dose methotrexate and anti-TNF; targeting angiogenesis and tissue damage pathways directly; antigen-specific therapy; potential combination of TNF and IL17 blockade; and targeting inhibitory receptors and regulatory T cells.
FDA Warns of Severe Joint Pain Risk with DPP-4 Diabetes Drugs
(Reuters)—A class of diabetes drugs that include Merck & Co Inc.’s Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday. The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006,…
Early, Aggressive Therapy for RA May Result in Cost Savings Long Term
By considering the long-term damage from early, aggressive rheumatoid arthritis, researchers in the UK were able to develop a model demonstrating the long-term cost effectiveness of more aggressive combination therapies v. short-term treatments…
FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
WASHINGTON (Reuters)—The U.S. Food and Drug Administration proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts. The FDA said its draft guidance is designed to prevent the inadvertent substitution of non-interchangeable products and to make it easier to monitor and track usage once…
Global Life Expectancy Rises, but People Live Sicker for Longer
LONDON (Reuters)—People around the world are living longer, but many are also living sicker lives for longer, according to a study of all major diseases and injuries in 188 countries. General health has improved worldwide, thanks to significant progress against infectious diseases, such as HIV/AIDS and malaria, in the past decade and gains in fighting…
AFIRM Act of 2015 Could Benefit Rheumatologists
New legislation has the potential to streamline the audit process for Medicare and Medicaid, taking a burden off small rheumatology practices…
Ustekinumab Found to Be Effective in Adolescents with Psoriasis
NEW YORK (Reuters Health)—Adolescents with moderate to severe psoriasis may respond to the human monoclonal antibody ustekinumab as well as adults, with no unexpected side effects, a new study found. The findings are exciting in part because patients in this age group have limited treatment options, the study’s lead author Dr. Ian Landells, of Memorial…
- « Previous Page
- 1
- …
- 562
- 563
- 564
- 565
- 566
- …
- 814
- Next Page »